Acute Pulmonary Injury in Hematology Patients Supported with Pathogen Reduced and Conventional Platelet Components

By sjmartinez • March 7, 2024

Wheeler AP, Snyder EL, Refaai MA, Cohn CS, Poisson J, Fontaine MJ, Sehl M, Nooka AK, Uhl L, Spinella PC, Fenelus M, Liles DK, Coyle T, Becker J, Jeng MR, Gehrie EA, Spencer BR, Young PP, Johnson AD, O'Brien J, Schiller GJ, Roback JD, Malynn E, Jackups R, Avecilla S, Liu K, Bentow S, Varrone J, Benjamin RJ, Corash L. Acute Pulmonary Injury in Hematology Patients Supported with Pathogen Reduced and Conventional Platelet Components. Blood Adv. 2024 Mar 6:bloodadvances.2023012425. doi: 10.1182/bloodadvances.2023012425. Epub ahead of print. PMID: 38447116.

Tags: Hematology/Oncology, Publications

Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2-targeted antibody-drug conjugates in breast and ovarian cancer

Thaker SK, Silverstein J, Konecny GE, Bardia A. Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2-targeted antibody-drug conjugates in breast[...]

Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma

Chan SL, Finn RS, Edeline J, Ogasawara S, Knox JJ, Daniele B, Ryoo BY, Merle P, Bouattour M, Lim HY, Chao Y, Yau T, Haber[...]

First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial

Sun JM, Chao Y, Kim SB, Rha SY, Evans TRJ, Strickland AH, Wainberg Z, Chau I, Pelles-Avraham S, Ajani J, Malhotra R, Liu Q, Li[...]